Overview: This Phase 3 trial, sponsored by Vergent Bioscience, Inc., evaluates abenacianine (VGT-309), an investigational fluorescent imaging agent that is administered intravenously 12 to 96 hours before lung surgery. During surgery, near-infrared (NIR) imaging is used to activate the agent, causing tumor cells to “light up” in real time and helping surgeons identify cancer lesions that may not be visible through standard surgical techniques. The study compares standard surgery alone against surgery enhanced with NIR imaging to determine whether the approach improves tumor detection and surgical outcomes. While not a synovial sarcoma-specific trial, this study is relevant to patients with synovial sarcoma who have developed lung metastases and are undergoing surgical resection.